Active, not recruitingNCT04602091
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
Studying NON RARE IN EUROPE: Rheumatoid arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Societe Francaise de Rhumatologie
- Principal Investigator
- Marie-Elise TRUCHETETCHU de Bordeaux - Pellegrin
- Intervention
- no intervention(other)
- Enrollment
- 2300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2030
Study locations (30)
- CH Antibes, Antibes, France
- Private office, Bayonne, France
- CH Franche Comte, Belfort, France
- CHU de Besançon, Besançon, France
- AP-HP Avicenne, Bobigny, France
- CHU de Bordeaux, Bordeaux, France
- CH Bourg-en-Bresse, Bourg-en-Bresse, France
- CHRU Brest, Brest, France
- CHU Caen, Caen, France
- CH Cannes, Cannes, France
- CH Chartres, Chartres, France
- CH Cholet, Cholet, France
- CHU Clermont Ferrand, Clermont-Ferrand, France
- CH Colombes, Colombes, France
- AP-HP Henri Mondor, Créteil, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Bordeaux PharmacoEpi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04602091 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Rheumatoid arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07137598A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)Hoffmann-La Roche
- RECRUITINGPHASE1NCT07200596The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy SubjectsGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2NCT07100938A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid ArthritisBeiGene
- RECRUITINGPHASE1NCT07040930Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.Changchun GeneScience Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07089381Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.Ain Shams University
- RECRUITINGNANCT06693479Could a Feedback Device Help Manage Work-related Shoulder Disorders?Laval University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06475495Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisCharite University, Berlin, Germany
- RECRUITINGNCT07315997The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) StudyBrigham and Women's Hospital
See all trials for NON RARE IN EUROPE: Rheumatoid arthritis →